FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385063982> ?p ?o ?g. }

• W4385063982 abstract "Ovarian cancer is a complex disease associated with multiple genetic and epigenetic alterations. The emergence of treatment resistance in most patients causes ovarian cancer to become incurable, and novel therapies remain necessary. We identified epigenetic regulator ATPase family AAA domain-containing 2 (ATAD2) is overexpressed in ovarian cancer and is associated with increased incidences of metastasis and recurrence. Genetic knockdown of ATAD2 or its pharmacological inhibition via ATAD2 inhibitor BAY-850 suppressed ovarian cancer growth and metastasis in both in vitro and in vivo models. Transcriptome-wide mRNA expression profiling of ovarian cancer cells treated with BAY-850 revealed that ATAD2 inhibition predominantly alters the expression of centromere regulatory genes, particularly centromere protein E (CENPE). In ovarian cancer cells, changes in CENPE expression following ATAD2 inhibition resulted in cell-cycle arrest and apoptosis induction, which led to the suppression of ovarian cancer growth. Pharmacological CENPE inhibition phenotypically recapitulated the cellular changes induced by ATAD2 inhibition, and combined pharmacological inhibition of both ATAD2 and CENPE inhibited ovarian cancer cell growth more potently than inhibition of either alone. Thus, our study identified ATAD2 as regulators of ovarian cancer growth and metastasis that can be targeted either alone or in combination with CENPE inhibitors for effective ovarian cancer therapy." @default.
• W4385063982 created "2023-07-23" @default.
• W4385063982 creator A5034886921 @default.
• W4385063982 creator A5035798595 @default.
• W4385063982 creator A5037329030 @default.
• W4385063982 creator A5059801211 @default.
• W4385063982 creator A5090735677 @default.
• W4385063982 creator A5091565304 @default.
• W4385063982 date "2023-07-21" @default.
• W4385063982 modified "2023-10-14" @default.
• W4385063982 title "ATAD2 is a driver and a therapeutic target in ovarian cancer that functions by upregulating CENPE" @default.
• W4385063982 cites W1512072225 @default.
• W4385063982 cites W1540284844 @default.
• W4385063982 cites W1960374325 @default.
• W4385063982 cites W1974266360 @default.
• W4385063982 cites W1981390480 @default.
• W4385063982 cites W1997981312 @default.
• W4385063982 cites W2003274318 @default.
• W4385063982 cites W2010233684 @default.
• W4385063982 cites W2010561642 @default.
• W4385063982 cites W2017928359 @default.
• W4385063982 cites W2034687480 @default.
• W4385063982 cites W2036530157 @default.
• W4385063982 cites W2047493748 @default.
• W4385063982 cites W2049375652 @default.
• W4385063982 cites W2055116570 @default.
• W4385063982 cites W2073773630 @default.
• W4385063982 cites W2090225407 @default.
• W4385063982 cites W2090578629 @default.
• W4385063982 cites W2103726956 @default.
• W4385063982 cites W2104765303 @default.
• W4385063982 cites W2105985632 @default.
• W4385063982 cites W2116102471 @default.
• W4385063982 cites W2116376484 @default.
• W4385063982 cites W2117692326 @default.
• W4385063982 cites W2119145839 @default.
• W4385063982 cites W2121300496 @default.
• W4385063982 cites W2123696077 @default.
• W4385063982 cites W2123784922 @default.
• W4385063982 cites W2124173308 @default.
• W4385063982 cites W2128904109 @default.
• W4385063982 cites W2131339364 @default.
• W4385063982 cites W2131593373 @default.
• W4385063982 cites W2132244795 @default.
• W4385063982 cites W2132680465 @default.
• W4385063982 cites W2142950644 @default.
• W4385063982 cites W2147106231 @default.
• W4385063982 cites W2147246240 @default.
• W4385063982 cites W2158994419 @default.
• W4385063982 cites W2162373413 @default.
• W4385063982 cites W2177274084 @default.
• W4385063982 cites W2211028825 @default.
• W4385063982 cites W2211308132 @default.
• W4385063982 cites W2252477019 @default.
• W4385063982 cites W2514207328 @default.
• W4385063982 cites W2743935521 @default.
• W4385063982 cites W2755644324 @default.
• W4385063982 cites W2765540468 @default.
• W4385063982 cites W2770554590 @default.
• W4385063982 cites W284033874 @default.
• W4385063982 cites W2886882464 @default.
• W4385063982 cites W2945043506 @default.
• W4385063982 cites W2956047368 @default.
• W4385063982 cites W2975140046 @default.
• W4385063982 cites W2990211334 @default.
• W4385063982 cites W3007931792 @default.
• W4385063982 cites W3010969972 @default.
• W4385063982 cites W3019558381 @default.
• W4385063982 cites W3049750006 @default.
• W4385063982 cites W3082075344 @default.
• W4385063982 cites W3135101421 @default.
• W4385063982 cites W3152492976 @default.
• W4385063982 cites W3171902378 @default.
• W4385063982 cites W3217220497 @default.
• W4385063982 cites W4200419028 @default.
• W4385063982 cites W4206161007 @default.
• W4385063982 cites W4210907022 @default.
• W4385063982 cites W4211203170 @default.
• W4385063982 cites W4225255163 @default.
• W4385063982 cites W4286852506 @default.
• W4385063982 cites W4295540029 @default.
• W4385063982 cites W4296806898 @default.
• W4385063982 cites W4315754639 @default.
• W4385063982 cites W4321166409 @default.
• W4385063982 doi "https://doi.org/10.1038/s41419-023-05993-9" @default.
• W4385063982 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37479754" @default.
• W4385063982 hasPublicationYear "2023" @default.
• W4385063982 type Work @default.
• W4385063982 citedByCount "0" @default.
• W4385063982 crossrefType "journal-article" @default.
• W4385063982 hasAuthorship W4385063982A5034886921 @default.
• W4385063982 hasAuthorship W4385063982A5035798595 @default.
• W4385063982 hasAuthorship W4385063982A5037329030 @default.
• W4385063982 hasAuthorship W4385063982A5059801211 @default.
• W4385063982 hasAuthorship W4385063982A5090735677 @default.
• W4385063982 hasAuthorship W4385063982A5091565304 @default.
• W4385063982 hasBestOaLocation W43850639821 @default.
• W4385063982 hasConcept C104317684 @default.
• W4385063982 hasConcept C121608353 @default.
• W4385063982 hasConcept C150194340 @default.

• next